Ethic Inc. Buys Shares of 10,411 Maravai LifeSciences Holdings, Inc. $MRVI

Ethic Inc. acquired a new stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,411 shares of the company’s stock, valued at approximately $26,000.

Other hedge funds also recently made changes to their positions in the company. Callan Family Office LLC purchased a new position in shares of Maravai LifeSciences in the 2nd quarter worth about $25,000. McAdam LLC purchased a new stake in shares of Maravai LifeSciences in the 1st quarter valued at $31,000. EntryPoint Capital LLC purchased a new position in Maravai LifeSciences in the 1st quarter worth $32,000. Aigen Investment Management LP bought a new stake in Maravai LifeSciences in the first quarter worth $37,000. Finally, Teacher Retirement System of Texas purchased a new stake in Maravai LifeSciences during the first quarter valued at about $37,000. 50.25% of the stock is owned by institutional investors.

Maravai LifeSciences Price Performance

MRVI opened at $3.14 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 4.49 and a current ratio of 5.16. The stock has a market capitalization of $801.83 million, a PE ratio of -2.31 and a beta of 0.33. The stock’s 50 day moving average price is $2.92 and its 200-day moving average price is $2.50. Maravai LifeSciences Holdings, Inc. has a 52-week low of $1.66 and a 52-week high of $8.29.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maravai LifeSciences in a report on Tuesday, October 14th. Royal Bank Of Canada reduced their price target on Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a research report on Tuesday, August 12th. Three analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.22.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.